A decision, likely to come in June, would be a major victory for the FDA’s authority to regulate prescription drugs and for abortion-rights advocates who have sought to protect access to mifepristone.
Related Posts
Obamacare returns to SCOTUS, with preventive care on the line
The lawsuit, brought by conservative employers in Texas, targets the expert panel that advises HHS on which preventive care services…
Detecting Covid surges is getting harder, thanks to a contract dispute
“The thing I’m concerned about is continuity of our surveillance data while this protest is playing out,” said Chad Gubala,…
Georgia’s public health insurance experiment is off to a slow start
Democrats have long tried to persuade red states to expand the federal Medicaid program and bring health insurance to more…